DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
GILEAD.
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH).
2019
Access:
We do not assume any responsibility for the contents of the web pages of other providers.